Grafting of 3D Bioprinting to In Vitro Drug Screening: A Review

Adv Healthc Mater. 2020 Apr;9(7):e1901773. doi: 10.1002/adhm.201901773. Epub 2020 Mar 3.

Abstract

The inadequacy of conventional cell-monolayer planar cultures and animal experiments in predicting the toxicity and clinical efficacy of drug candidates has led to an imminent need for in vitro methods with the ability to better represent in vivo conditions and facilitate the systematic investigation of drug candidates. Recent advances in 3D bioprinting have prompted the precise manipulation of cells and biomaterials, rendering it a promising technology for the construction of in vitro tissue/organ models and drug screening devices. This review presents state-of-the-art in vitro methods used for preclinical drug screening and discusses the limitations of these methods. In particular, the significance of constructing 3D in vitro tissue/organ models and microfluidic analysis devices for drug screening is emphasized, and a focus is placed on the grafting process of 3D bioprinting technology to the construction of such models and devices. The in vitro methods for drug screening are generalized into three types: mini-tissue, organ-on-a-chip, and tissue/organ construct. The revolutionary process of the in vitro methods is demonstrated in detail, and relevant studies are listed as examples. Specifically, the tumor model is adopted as a precedent to illustrate the possible grafting of 3D bioprinting to antitumor drug screening.

Keywords: 3D bioprinting; drug screening devices; in vitro drug screening; mini-tissue; organ-on-a-chip; tissue/organ construct.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Biocompatible Materials
  • Bioprinting*
  • Drug Evaluation, Preclinical
  • Lab-On-A-Chip Devices
  • Printing, Three-Dimensional
  • Tissue Engineering

Substances

  • Biocompatible Materials